PT2254598E - Combinação de agonistas nicotínicos alfa 7 e antipsicóticos - Google Patents

Combinação de agonistas nicotínicos alfa 7 e antipsicóticos

Info

Publication number
PT2254598E
PT2254598E PT97095772T PT09709577T PT2254598E PT 2254598 E PT2254598 E PT 2254598E PT 97095772 T PT97095772 T PT 97095772T PT 09709577 T PT09709577 T PT 09709577T PT 2254598 E PT2254598 E PT 2254598E
Authority
PT
Portugal
Prior art keywords
combination
antipsychotics
alpha
nicotinic agonists
nicotinic
Prior art date
Application number
PT97095772T
Other languages
English (en)
Portuguese (pt)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen G Jordan
Terry Hauser
Sharon R Letchworth
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PT2254598E publication Critical patent/PT2254598E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT97095772T 2008-02-13 2009-02-13 Combinação de agonistas nicotínicos alfa 7 e antipsicóticos PT2254598E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
PT2254598E true PT2254598E (pt) 2013-10-16

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97095772T PT2254598E (pt) 2008-02-13 2009-02-13 Combinação de agonistas nicotínicos alfa 7 e antipsicóticos

Country Status (25)

Country Link
US (1) US20110059947A1 (enExample)
EP (2) EP2254598B1 (enExample)
JP (1) JP2011511845A (enExample)
KR (1) KR20100113163A (enExample)
CN (2) CN101977628A (enExample)
AU (1) AU2009214625A1 (enExample)
BR (1) BRPI0907570A2 (enExample)
CA (1) CA2715268A1 (enExample)
CO (1) CO6290706A2 (enExample)
CY (1) CY1114492T1 (enExample)
DK (1) DK2254598T3 (enExample)
EC (1) ECSP10010471A (enExample)
ES (1) ES2430622T3 (enExample)
HR (1) HRP20130749T1 (enExample)
IL (1) IL207389A0 (enExample)
MX (1) MX2010008875A (enExample)
NZ (1) NZ587312A (enExample)
PL (1) PL2254598T3 (enExample)
PT (1) PT2254598E (enExample)
RS (1) RS52941B (enExample)
RU (1) RU2481123C2 (enExample)
SG (1) SG188144A1 (enExample)
SI (1) SI2254598T1 (enExample)
WO (1) WO2009102962A2 (enExample)
ZA (1) ZA201005999B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2619205B1 (en) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
EP2665478A1 (en) * 2011-01-18 2013-11-27 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
BR0016168A (pt) * 1999-12-10 2002-08-20 Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
AU2001266100B9 (en) * 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
JP2006510664A (ja) * 2002-12-06 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー １−アザビシクロ［２．２．２］オクト置換フロ［２，３−ｃ］ピリジニルカルボキサミドの結晶性フマル酸塩及び該塩を含む組成物並びにその製造方法
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
CN101977628A (zh) 2011-02-16
PL2254598T3 (pl) 2013-12-31
EP2254598B1 (en) 2013-07-10
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
SG188144A1 (en) 2013-03-28
CO6290706A2 (es) 2011-06-20
ES2430622T3 (es) 2013-11-21
RS52941B (sr) 2014-02-28
WO2009102962A3 (en) 2009-10-08
HRP20130749T1 (en) 2013-10-11
AU2009214625A1 (en) 2009-08-20
SI2254598T1 (sl) 2013-10-30
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ZA201005999B (en) 2011-05-25
NZ587312A (en) 2011-12-22
KR20100113163A (ko) 2010-10-20
ECSP10010471A (es) 2010-10-30
MX2010008875A (es) 2010-08-31
DK2254598T3 (da) 2013-07-29
CA2715268A1 (en) 2009-08-20
BRPI0907570A2 (pt) 2019-09-24
CN103143023A (zh) 2013-06-12
HK1147954A1 (en) 2011-08-26
RU2481123C2 (ru) 2013-05-10
US20110059947A1 (en) 2011-03-10
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
MX2010008875A (es) Agonistas nicotinicos alfa 7 y antipsicoticos.
IL262838A (en) Guanylate cyclase agonists for use in the treatment of hypercholesterolemia
SG171584A1 (en) Nanoparticulate metal boride composition and its use for identification- marking plastic parts
ZA200809941B (en) 2-anilino-4-(heterocyclic)amino-pyrimidines
IL184324A0 (en) Pyy agonists and uses thereof
IL184535A0 (en) Peracid/peroxide composition and use thereof as an anti-microbial and photosensitizer
IL193042A0 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists
ZA201103044B (en) Conjugates of glp-1 agonists and uses thereof
ZA200706030B (en) GLP-1 agonists, compositions, methods and uses
IL188329A0 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
IL197244A0 (en) Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
EP2091957A4 (en) HYDROGEN CLEAVAGE COMPOSITION
IL215050A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
IL212364A0 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
DK1987121T3 (da) Biocid hydrogenperoxidsammensætning med forøget aktivitet
PL3838303T3 (pl) Niewodna kompozycja powlekająca do artykułów elastomerowych i wyroby zawierające tę kompozycję
MY167138A (en) Smoking article component
IL187105A0 (en) Novel compunds as glp-i agonists
ZA200805203B (en) Lubricant composition with improved solvency
EP2188231A4 (en) OXYGEN ABSORBING COMPOSITION
GB0603975D0 (en) Methods and agents for reducing oxidative stress
IL190045A0 (en) Use of c3-c10 17 alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
EP2303016A4 (en) METHOD AND USE FOR THE USE OF SELECTIVE DELTA OPIOID RECEPTOR 1 AGONISTS, DELTA OPIOID RECEPTOR 2 AGONISTS AND / OR MU OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ACTIVE SUBSTANCES
GB2429656B (en) Cue tip shaper
SI2134330T1 (sl) Kombinacije 5-HT2A inverznih agonistov in antagonistov z antipsihotiki